Corrigendum to "Immunogenicity, reactogenicity and persistence of meningococcal A, C,W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years" [Vaccine 27 (2009) 161-168] (DOI:10.1016/j.vaccine.2008.08.075);Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years

Vaccine

Volumn 27, Issue 1, 2009, Pages 161-168

  Østergaard, Lars ^a   Lebacq, Edouard ^b   Poolman, Jan ^c   Maechler, Gudrun ^d   Boutriau, Dominique ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Clinique Notre Dame de Grace   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GLAXOSMITHKLINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENCEVAX; MENINGOCOCCAL ACWY TETANUS TOXOID VACCINE; MENINGOCOCCUS VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BELGIUM; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CONJUGATION; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALE; MENINGOCOCCOSIS; NAUSEA; NECK PAIN; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; SWELLING; URTICARIA; VOLUNTEER;

EID: 56949108640     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.037     Document Type: Erratum

References (34)

1. Findlow J., Balmer P., Yero D., Niebla O., Pajón R., and Borrow R. Neisseria vaccines 2007. Expert Rev Vaccines 6 4 (2007) 485-489
2. European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe; 2006. Available from www.euibis.org/documents/2006_meningo.pdf (accessed January 22, 2008).
3. Harrison L.H., Dwyer D.M., Maples C.T., and Billmann L. Risk of meningococcal infection in college students. JAMA 281 20 (1999) 1906-1910
4. Harrison L.H., Pass M.A., Mendelsohn A.B., Egri M., Rosenstein N.E., Bustamante A., et al. Invasive meningococcal disease in adolescents and young adults. JAMA 286 6 (2001) 694-699
5. Brandtzaeg P., and van Deuren M. Meningococcal disease at the start of the 21st century. Adv Paediatr 52 (2005) 129-162
6. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93 4 (1999) 341-353
7. Njanpop-Lafourcade B.M., Parent du Châtelet I., Sanou O., Alonso J.M., and Taha M.K. The establishment of Neisseria meningitidis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the presence of serogroup A isolate in Burkina Faso. Microbes Infect 7 (2005) 645-649
8. World Health Organization, Geneva. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 80 37 (2005) 313-320
9. Lingappa J.R., Al-Rabeah A.M., Hajjeh R., Mustafa T., Fatani A., Al-Bassam T., et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 9 6 (2003) 665-671
10. World Health Organization. Meningococcal disease, African meningitis belt, epidemic season. Wkly Epidemiol Rec 81 13 (2006) 119-120
11. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., and Mainassara H.B. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44 (2007) 657-663
12. Harrison L.H. A multivalent conjugate vaccine for prevention of meningococcal disease in infants. JAMA 299 2 (2008) 217-219
13. Canada Communable Disease Report. Available from http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/dr3310ea.html (accessed January 25, 2008) 2007; 33(10).
14. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (2001) S58-S67
15. Trotter C., Andrews N., Kaczmarski E., Miller E., and Ramsay M. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
16. De Wals P., Deceuninck G., Boulianne N., and De Serres G.S. Effectiveness of serogroup C meningococcal conjugate vaccine (C-MCV): a 5-year follow-up in Quebec, Canada. Proceedings of the 45th Annual Meeting of Infectious Diseases Society of America. San Diego, October 4-7 (2007)
17. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336 (2008) 1487-1491
18. Maiden M.C., Stuart J.M., and UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 9320 (2002) 1829-1831
19. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 7385 (2003) 365-366
20. De Wals P., Coudeville L., Trottier P., Chevat C., Erickson L.J., and Nguyen V.H. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 25 29 (2007) 5433-5440
21. Pace D., and Pollard A.J. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child 92 10 (2007) 909-915
22. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4 2 (1997) 156-167
23. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69 (2001) 1568-1573
24. Borrow R., Balmer P., and Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23 17-18 (2005) 2222-2227
25. Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR 2006; 55(37):1016-17.
26. WHO Expert Committee on Biological Standardization. 31st Report. WHO Technical Report Series 1981; 658:174-83.
27. Peltola H. Meningococcal vaccines. Current status and future possibilities. Drugs 55 3 (1998) 347-366
28. World Health Organization. Group A and C meningococcal vaccines. WHO position paper. WER 1999; 74:297-304.
29. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 297 (1977) 686-691
30. Austrian R. Pneumococcal otitis media and pneumococcal vaccines, a historical perspective. Vaccine 19 (2001) S71-S77
31. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel A., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 159 10 (2005) 907-913
32. Jackson L.A., Jacobson R.M., Reisinger K.S., Ganju J., Kartsen A., and Dull P.M. Immunogenicity at 12 months post-vaccination with novartis vaccines' tetravalent glycoconjugate meningococcal ACWY vaccine in adolescents. Proceedings of the 45th annual meeting of infectious diseases society of America. San Diego, October 4-7 (2007)
33. ® in adolescents. Pediatric Academic Sciences & Asian Society for Pediatric Research Joint Meeting. Honolulu, Hawaii, May 2-6 (2008) [Abstract]
34. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Préziosi M.P., et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 25 Suppl 1 (2007) A101-A107